Llwytho...
Outcomes after progression of disease with anti-PD-1/PDL1 therapy for advanced melanoma
BACKGROUND: Over half of patients treated with antibodies blocking programmed death-1 receptor (anti-PD-1) for melanoma experience disease progression. We aimed to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed on anti-PD-1 therapy. METHODS: We evaluate...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7695037/ https://ncbi.nlm.nih.gov/pubmed/32463489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32984 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|